Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

AGALSIDASE ALFA 3.5MG/3.5ML CONCENTRATE FOR SOLUTION FOR INFUSION, 3.5 mL, vial, PACK OF 1 (HOMECARE)

Belfast Health and Social Care Trust

This public procurement record has 2 releases in its history.

Award

08 Sep 2026 at 10:22

UK6 - Contract Award Notice
Award

07 Sep 2026 at 13:21

UK5 - Transparency Notice
Summary of the contracting process

Belfast Health & Social Care Trust is procuring agalsidase alfa 3.5 mg/3.5 ml concentrate for solution for infusion, supplied as 3.5 ml single-vial packs for homecare use. This is a pharmaceutical goods requirement intended to support patients receiving treatment at home and maintain continuity of care. The named product is a specialist medicine rather than a general medicines supply. Delivery is for activity in the United Kingdom, with the procurement managed by the Trust in Belfast. The requirement covers one completed lot and is focused on the supply of the specified medicine and associated homecare support. Businesses active in pharmaceutical supply, specialist medicines distribution or homecare treatment logistics would find the subject matter relevant, particularly where they can support uninterrupted patient treatment.

The procurement has reached the award stage: Sciensus Pharma Services Limited was selected as supplier, although the award is recorded as pending. The Trust used a direct award procedure, justified by the need to obtain essential medicines from this supplier for continuity of patient care and homecare support, rather than by competition. The award date was 8 September 2026. The awarded value is £670,000 including tax. The award contract period runs from 19 September 2026 to 30 September 2028. A standstill period ends on 18 September 2026, with contract signature scheduled for 19 September 2026. The procurement is above the relevant threshold. Evaluation was therefore based on the direct-award rationale and continuity requirement rather than a competitive price-and-quality assessment.

For a supplier assessing future demand from this buyer, the procurement demonstrates a requirement for reliable access to a specialist pharmaceutical product used in homecare infusion treatment. A credible competitor would need the regulatory, manufacturing or distribution capability to source and supply agalsidase alfa in the specified presentation, together with dependable stock management and delivery arrangements for patients receiving care at home. Experience supporting continuity of treatment, coordinating with healthcare services and managing time-sensitive medicine fulfilment would be commercially relevant. Suppliers would also need to understand the Trust’s Northern Ireland healthcare environment and demonstrate that their operating model can provide consistent patient support, not simply wholesale product delivery. The direct-award rationale indicates that uninterrupted care and supplier-specific continuity were central considerations.

How relevant is this notice?

Notice Information

Notice Title

AGALSIDASE ALFA 3.5MG/3.5ML CONCENTRATE FOR SOLUTION FOR INFUSION, 3.5 mL, vial, PACK OF 1 (HOMECARE)

Notice Description

Procurement of AGALSIDASE ALFA 3.5MG/3.5ML CONCENTRATE FOR SOLUTION FOR INFUSION, 3.5 mL, vial, PACK OF 1 (HOMECARE)

Procurement Information

These essential medicines are required from this supplier to ensure continuity of patient care, specifically for homecare support. The absence of competition is not the artificial narrowing of the parameters of the procurement.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06f379
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/084738-2026
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£670,000 £500K-£1M
Contracts Value
Not specified

Notice Dates

Publication Date
8 Sep 20261 weeks ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
8 Sep 20261 weeks ago
Contract Period
19 Sep 2026 - 30 Sep 2028 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
Belfast Health and Social Care Trust
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
BELFAST
Postcode
BT12 6BA
Postcode Area
Northern Ireland
Country
Northern Ireland
Major Region (ITL 1)
TLN Northern Ireland
Basic Region (ITL 2)
TLN0 Northern Ireland
Small Region (ITL 3)
TLN06 Belfast
Delivery Location
Not specified
Local Authority
Belfast
Electoral Ward
Falls
Westminster Constituency
Belfast West

Supplier Information

Number of Suppliers
1
Supplier Name

SCIENSUS PHARMA SERVICES LIMITED

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...